There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stemline Therapeutics Inc (STML), Aduro BioTech (ADRO) and G1 Therapeutics Inc (GTHX) with bullish sentiments.
Stemline Therapeutics Inc (STML)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Stemline Therapeutics Inc, with a price target of $38. The company’s shares closed on Friday at $13.20, close to its 52-week low of $12.60.
Selvaraju noted:
“Our 12-month price target is derived from a discounted cash flow-based asset value of $1.2B for 15% discount rate and 2% terminal growth rate. Probabilities of success ascribed to SL-401 and SL-701 are 90% and 45%, respectively.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.9% and a 28.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Fennec Pharmaceuticals Inc.
Currently, the analyst consensus on Stemline Therapeutics Inc is a Strong Buy with an average price target of $35.50, a 168.9% upside from current levels. In a report issued on November 8, Cowen & Co. also reiterated a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Aduro BioTech (ADRO)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aduro BioTech today and set a price target of $8.30. The company’s shares closed on Friday at $3.63, close to its 52-week low of $3.61.
Pantginis commented:
“Valuation and risks to price target achievement. We maintain our Buy rating, and $8.30 price target. Our target is based on our clinical net present value (NPV) model, which derives value from across Aduro’s assets but primarily for ADU-S100. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -16.5% and a 27.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Aduro BioTech has an analyst consensus of Strong Buy, with a price target consensus of $9.15, implying a 152.1% upside from current levels. In a report issued on October 30, Oppenheimer also reiterated a Buy rating on the stock with a $10 price target.
.
G1 Therapeutics Inc (GTHX)
H.C. Wainwright analyst Edward White maintained a Buy rating on G1 Therapeutics Inc today and set a price target of $75. The company’s shares closed on Friday at $45.67.
White noted:
“We base our $75 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC.”
According to TipRanks.com, White is a 5-star analyst with an average return of 13.9% and a 45.3% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics Inc with a $77 average price target, which is a 68.6% upside from current levels. In a report issued on November 8, Cowen & Co. also maintained a Buy rating on the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
